Wilken). mutation. The concentration of sEGFR in pretreatment serum was positively correlated with overall survival (OS), but not with responsiveness to gefitinib in this small patient cohort. Expression of tumor biomarkers was not associated with PFS or OS. Co-expression of ER with PRA in primary and recurrent tumors, and pEGFR with pERK in primary tumors was observed. Conclusions This treatment regimen was tolerable but lacked sufficient efficacy to warrant further evaluation in this setting. The possible association between serum sEGFR concentrations and OS, and temporal changes in expression of pEGFR and pERK and the documented CR of one patient are interesting and warrant additional investigation. and studies of endometrial cancer have implicated EGFR as an important regulator of cell proliferation and survival [16C21]. However, tumor EGFR expression has been associated with adverse outcomes in endometrial cancer only in some studies [19, 22C24], whereas in others, EGFR is not a significant marker of survival [25C28]. Serum sEGFR concentrations have not previously been examined in endometrial cancer patients. Gefitinib has substantial growth inhibitory and apoptotic inductive activity in a number of and studies using tumor cell lines and xenografts, including those of endometrial origin [17, 29C33]. Only one study thus far has reported around the efficacy of an EGFR tyrosine kinase inhibitor (i.e. erlotinib) for the treatment of patients with endometrial cancer [34]. Gefitinib is usually safe and well tolerated with some associated dermatological and gastrointestinal adverse events. The primary endpoint of this phase II clinical trial was progression-free survival (PFS) at six months for daily oral gefitinib (500 mg) as a treatment for recurrent or persistent endometrial cancer. Overall survival (OS) was included as a secondary endpoint. The potential prognostic and predictive clinical utility of several candidate biomarkers previously associated with steroid receptor and EGFR signal transduction pathways in endometrial cancer were evaluated. MATERIALS AND METHODS This was a Gynecologic Oncology Group (GOG) sponsored non-randomized, multicenter phase II open-label trial, designated GOG 229C, which evaluated the efficacy and safety of gefitinib (supplied by AstraZeneca, Cheshire, Rabbit Polyclonal to OR13C4 UK) in 26 evaluable patients with endometrial carcinoma who had persistent or recurrent disease following front-line chemotherapy and higher priority protocols. Clinical and laboratory toxicities were monitored and graded according to the National Malignancy Institute Common Toxicity Criteria (CTC) Version 2.0. All adverse events were recorded and graded according to the CTC, Version 2.0 (http://ctep.info.nih.gov). Radiographic studies were performed at two-month intervals. All patients who progressed were followed to assess OS. Eligibility Patients with histologically confirmed, recurrent or persistent endometrial carcinoma after at least one chemotherapeutic regimen, and with at least one measurable lesion (at least 20 mm by palpation, x-ray, CT scan, or MRI, or at least 10 mm by spiral CT scan) were eligible for this trial. Each patient provided written consent for the protocol including the translational research component with annual Institution Review Board approval at each of the participating institutions and laboratories in accordance with local, state, and federal regulations and guidelines. Study Design and Treatment Plan Gefitinib was administered at a dose of 500 mg per day orally. Each 28 day period was considered a cycle. If side effects were not severe and requirements for monitoring toxicity were met, patients were eligible to remain on the study agent until progression. Management of Toxicity In general, gefitinib was withheld in patients with grade 2 or greater toxicities until resolution, and patients were then restarted on a reduced dose of 250 mg/day. No dose reductions below 250 mg were allowed. If toxicities did not resolve to grade 1 or baseline after two weeks of withholding gefitinib (15 days) for any toxicity, the patient was to be removed from study. On-Study Evaluation Details are provided in the Supplemental Methods. Biological samples Archived formalin-fixed, paraffin-embedded (FFPE) primary tumor tissue from the initial hysterectomy, and serial pre- and post-treatment biopsies (core biopsies or final needle aspirates) of recurrent or persistent tumor were required Tacrolimus monohydrate for this protocol. Patients also were asked to provide serum samples prior to gefitinib treatment. See Supplemental Methods for additional details. Analysis of EGFR Mutation Status Genomic DNA was extracted from FFPE tumor tissue using a TrimGen DNA purification kit (TrimGen Corp, Sparks, MD) according to the kit instructions. EGFR exons 18C21 were amplified by polymerase chain reaction (PCR) as published previously and the amplicons sequenced as described in Supplemental Methods [35]. Analysis of Serum sEGFR Concentrations Twenty-four (of 26 evaluable) patients provided baseline serum samples prior to gefitinib treatment for sEGFR quantitation. Serum sEGFR.recurrent pre-treatment tumors (Figures 3 and ?and4).4). to gefitinib in this small patient cohort. Expression of tumor biomarkers was not associated with PFS or OS. Co-expression of ER with PRA in primary and recurrent tumors, and pEGFR with pERK in primary tumors was observed. Conclusions This treatment regimen was tolerable but lacked sufficient efficacy to warrant further evaluation in this setting. The possible association between serum sEGFR concentrations and OS, and temporal changes in expression of pEGFR and pERK and the documented CR of one patient are interesting and warrant additional investigation. and studies of endometrial cancer have implicated EGFR as an important regulator of cell proliferation and survival [16C21]. However, tumor EGFR manifestation has been associated with adverse results in endometrial malignancy only in some studies [19, 22C24], whereas in others, EGFR is not a significant marker of survival [25C28]. Serum sEGFR concentrations have not previously been examined in endometrial malignancy individuals. Gefitinib offers substantial growth inhibitory and apoptotic inductive activity in a number of and studies using tumor cell lines and xenografts, including those of endometrial source [17, 29C33]. Only one study thus far offers reported within the efficacy of an EGFR tyrosine kinase inhibitor (i.e. erlotinib) for the treatment of individuals with endometrial malignancy [34]. Gefitinib is definitely safe and well tolerated with some connected dermatological and gastrointestinal adverse events. The primary endpoint of this phase II medical trial was progression-free survival (PFS) at six months for daily oral gefitinib (500 mg) as a treatment for recurrent or prolonged endometrial cancer. Overall survival (OS) was included as a secondary endpoint. The potential prognostic and predictive medical utility of several candidate biomarkers previously associated with steroid receptor and EGFR transmission transduction pathways in endometrial malignancy were evaluated. MATERIALS AND METHODS This was a Gynecologic Oncology Group (GOG) sponsored non-randomized, multicenter phase II open-label trial, designated GOG 229C, which evaluated the effectiveness and security of gefitinib (supplied by AstraZeneca, Cheshire, UK) in 26 evaluable individuals with endometrial carcinoma who experienced persistent or recurrent disease following front-line chemotherapy and higher priority protocols. Clinical and laboratory toxicities were monitored and graded according to the National Tumor Institute Common Toxicity Criteria (CTC) Version 2.0. All adverse events were recorded and graded according to the CTC, Version 2.0 (http://ctep.info.nih.gov). Radiographic studies were performed at two-month intervals. All individuals who progressed were adopted to assess OS. Eligibility Individuals with histologically confirmed, recurrent or prolonged endometrial carcinoma after at least one chemotherapeutic routine, and with at least one measurable lesion (at least 20 mm by palpation, x-ray, CT scan, or MRI, or at least 10 mm by spiral CT scan) were eligible for this trial. Each individual provided written consent for the protocol including the translational study component with annual Institution Review Board authorization at each of the participating organizations and laboratories in accordance with local, state, and federal regulations and guidelines. Study Design and Treatment Plan Gefitinib was given at a dose of 500 mg per day orally. Each 28 day time period was regarded as a cycle. If side effects were not severe and requirements for monitoring toxicity were met, individuals were eligible to remain on the study agent until progression. Management of Toxicity In general, gefitinib was withheld in individuals with grade 2 or higher toxicities until resolution, and individuals were then restarted on a reduced dose of 250 mg/day time. No dose reductions below 250 mg were allowed. If toxicities did not resolve to grade 1 or baseline after two weeks of withholding gefitinib (15 days) for any toxicity, the patient was to be removed from study. On-Study Evaluation Details are provided in the Supplemental Methods. Biological examples Archived formalin-fixed, paraffin-embedded (FFPE) principal tumor tissues from the original hysterectomy, and serial pre- and post-treatment biopsies (primary biopsies or last needle aspirates) of repeated or consistent tumor were necessary for this process. Patients also had been asked to supply serum samples ahead of gefitinib treatment. Find Supplemental Options for extra details. Evaluation of EGFR Mutation Position Genomic DNA was extracted from FFPE tumor tissues utilizing a TrimGen DNA purification package (TrimGen Corp, Sparks, MD) based on the package guidelines. EGFR exons 18C21 had been amplified by polymerase string.sEGFR amounts had been categorized seeing that high or low.
sEGFR?Low121201111.64.1?Great12111931.911.0Total242312041.86.8 Open in another window
?Low121.00Referent1.00Referent?Great120.57(0.25C1.34)0.32(0.13C0.80) Open in another window Tumor Biomarker Analyses Recurrent and Principal tumor samples were assessed by immunohistochemistry for expression of EGFR, Ki67, ER, PRA, PRB, turned on (phosphorylated) EGFR (pEGFR) and ERK (pERK). sEGFR in pretreatment serum was favorably correlated with general survival (Operating-system), however, not with responsiveness to gefitinib within this little patient cohort. Appearance of tumor biomarkers had not been connected with PFS or Operating-system. Co-expression of ER with PRA in repeated and principal tumors, and pEGFR with benefit in principal tumors was noticed. Conclusions This treatment program was tolerable but lacked enough efficiency to warrant additional evaluation within this placing. The feasible association between serum sEGFR concentrations and Operating-system, and temporal adjustments in appearance of pEGFR and benefit and the noted CR of 1 affected individual are interesting and warrant extra investigation. and research of endometrial cancers have got implicated EGFR as a significant regulator of cell proliferation and success [16C21]. Nevertheless, tumor EGFR appearance continues to be associated with undesirable final results in endometrial cancers only in a few research [19, 22C24], whereas in others, EGFR isn’t a substantial marker of success [25C28]. Serum sEGFR concentrations never have previously been analyzed in endometrial cancers sufferers. Gefitinib provides substantial development inhibitory and apoptotic inductive activity in several and research using tumor cell lines and xenografts, including those of endometrial origins [17, 29C33]. Only 1 study so far provides reported in the efficacy of the EGFR tyrosine kinase inhibitor (i.e. erlotinib) for the treating sufferers with endometrial cancers [34]. Gefitinib is certainly secure and well tolerated with some linked dermatological and gastrointestinal undesirable events. The principal endpoint of the phase II scientific trial was progression-free survival (PFS) at half a year for daily dental gefitinib (500 mg) as cure for repeated or consistent endometrial cancer. General survival (Operating-system) was included as a second endpoint. The prognostic and predictive scientific utility of many applicant biomarkers previously connected with steroid Tacrolimus monohydrate receptor and EGFR indication transduction pathways in endometrial cancers were evaluated. Components AND METHODS This is a Gynecologic Oncology Group (GOG) sponsored non-randomized, multicenter stage II open-label trial, specified GOG 229C, which examined the effectiveness and protection of gefitinib (given by AstraZeneca, Cheshire, UK) in 26 evaluable individuals with endometrial carcinoma who got persistent or repeated disease pursuing front-line chemotherapy and higher concern protocols. Clinical and lab toxicities were supervised and graded based on the Country wide Cancers Institute Common Toxicity Requirements (CTC) Edition 2.0. All undesirable events were documented and graded based on the CTC, Edition 2.0 (http://ctep.info.nih.gov). Radiographic research had been performed at two-month intervals. All individuals who progressed had been adopted to assess Operating-system. Eligibility Individuals with histologically verified, recurrent or continual endometrial carcinoma after at least one chemotherapeutic routine, and with at least one measurable lesion (at least 20 mm by palpation, x-ray, CT scan, or MRI, or at least 10 mm by spiral CT scan) had been qualified to receive this trial. Each affected person provided created consent for the process like the translational study component with annual Organization Review Board authorization at each one of the taking part organizations and laboratories relative to local, condition, and federal rules and guidelines. Research Design and TREATMENT SOLUTION Gefitinib was given at a dosage of 500 mg each day orally. Each 28 day time period was regarded as a routine. If unwanted effects were not serious and requirements for monitoring toxicity had been met, individuals were permitted remain on the analysis agent until development. Administration of Toxicity Generally, gefitinib was withheld in individuals with quality 2 or higher toxicities until quality, and individuals were after that restarted on a lower life expectancy dosage of 250 mg/day time. No dosage.At two years, three individuals survived, each of whom had progressive disease. with PRA in major and repeated tumors, and pEGFR with benefit in major tumors was noticed. Conclusions This treatment routine was tolerable but lacked adequate effectiveness to warrant additional Tacrolimus monohydrate evaluation with this establishing. The feasible association between serum sEGFR concentrations and Operating-system, and temporal adjustments in manifestation of pEGFR and benefit and the recorded CR of 1 affected person are interesting and warrant extra investigation. and research of endometrial tumor possess implicated EGFR as a significant regulator of cell proliferation and success [16C21]. Nevertheless, tumor EGFR manifestation continues to be associated with undesirable results in endometrial tumor only in a few research [19, 22C24], whereas in others, EGFR isn’t a substantial marker of success [25C28]. Serum sEGFR concentrations never have previously been analyzed in endometrial tumor individuals. Gefitinib offers substantial development inhibitory and apoptotic inductive activity in several and research using tumor cell lines and xenografts, including those of endometrial source [17, 29C33]. Only 1 study so far provides reported over the efficacy of the EGFR tyrosine kinase inhibitor (i.e. erlotinib) for the treating sufferers with endometrial cancers [34]. Gefitinib is normally secure and well tolerated with some linked dermatological and gastrointestinal undesirable events. The principal endpoint of the phase II scientific trial was progression-free survival (PFS) at half a year for daily dental gefitinib (500 mg) as cure for repeated or consistent endometrial cancer. General survival (Operating-system) was included as a second endpoint. The prognostic and predictive scientific utility of many applicant biomarkers previously connected with steroid receptor and EGFR indication transduction pathways in endometrial cancers were evaluated. Components AND METHODS This is a Gynecologic Oncology Group (GOG) sponsored non-randomized, multicenter stage II open-label trial, specified GOG 229C, which examined the efficiency and basic safety of gefitinib (given by AstraZeneca, Cheshire, UK) in 26 evaluable sufferers with endometrial carcinoma who acquired persistent or repeated disease pursuing front-line chemotherapy and higher concern protocols. Clinical and lab toxicities were supervised and graded based on the Country wide Cancer tumor Institute Common Toxicity Requirements (CTC) Edition 2.0. All undesirable events were documented and graded based on the CTC, Edition 2.0 (http://ctep.info.nih.gov). Radiographic research had been performed at two-month intervals. All sufferers who progressed had been implemented to assess Operating-system. Eligibility Sufferers with histologically verified, recurrent or consistent endometrial carcinoma after at least one chemotherapeutic program, and with at least one measurable lesion (at least 20 mm by palpation, x-ray, CT scan, or MRI, or at least 10 mm by spiral CT scan) had been qualified to receive this trial. Each affected individual provided created consent for the process like the translational analysis component with annual Organization Review Board acceptance at each one of the taking part establishments and laboratories relative to local, condition, and federal rules and guidelines. Research Design and TREATMENT SOLUTION Gefitinib was implemented at a dosage of 500 mg each day orally. Each 28 time period was regarded a routine. If unwanted effects were not serious and requirements for monitoring toxicity had been met, sufferers were permitted remain on the analysis agent until development. Administration of Toxicity Generally, gefitinib was withheld in sufferers with quality 2 or better toxicities until quality, and sufferers were restarted on a lower life expectancy dosage then.The patient who achieved a CR and three of four patients with PFS six months had high baseline serum sEGFR concentrations. (Operating-system), however, not with responsiveness to gefitinib within this little patient cohort. Appearance of tumor biomarkers had not been connected with PFS or Operating-system. Co-expression of ER with PRA in principal and repeated tumors, and pEGFR with benefit in principal tumors was noticed. Conclusions This treatment program was tolerable but lacked enough efficiency to warrant additional evaluation within this placing. The feasible association between serum sEGFR concentrations and Operating-system, and temporal adjustments in appearance of pEGFR and benefit and the noted CR of 1 affected individual are interesting and warrant extra investigation. and research of endometrial cancers have got implicated EGFR as a significant regulator of cell proliferation and success [16C21]. Nevertheless, tumor EGFR appearance continues to be associated with undesirable final results in endometrial cancers only in a few research [19, 22C24], whereas in others, EGFR isn’t a substantial marker of survival [25C28]. Serum sEGFR concentrations have not previously been examined in endometrial malignancy individuals. Gefitinib offers substantial growth inhibitory and apoptotic inductive activity in a number of and studies using tumor cell lines and xenografts, including those of endometrial source [17, 29C33]. Only one study thus far offers reported within the efficacy of an EGFR tyrosine kinase inhibitor (i.e. erlotinib) for the treatment of individuals with endometrial malignancy [34]. Gefitinib is definitely safe and well tolerated with some connected dermatological and gastrointestinal adverse events. The primary endpoint of this phase II medical trial was progression-free survival (PFS) at six months for daily oral gefitinib (500 mg) as a treatment for recurrent or prolonged endometrial cancer. Overall survival (OS) was included as a secondary endpoint. The potential prognostic and predictive medical utility of several candidate biomarkers previously associated with steroid receptor and EGFR transmission transduction pathways in endometrial malignancy were evaluated. MATERIALS AND METHODS This was a Gynecologic Oncology Group (GOG) sponsored non-randomized, multicenter phase II open-label trial, designated GOG 229C, which evaluated the effectiveness and security of gefitinib (supplied by AstraZeneca, Cheshire, UK) in 26 evaluable individuals with endometrial carcinoma who experienced persistent or recurrent disease following front-line chemotherapy and higher priority protocols. Clinical and laboratory toxicities were monitored and graded according to the National Malignancy Institute Common Toxicity Criteria (CTC) Version 2.0. All adverse events were recorded and graded according to the CTC, Version 2.0 (http://ctep.info.nih.gov). Radiographic studies were performed at two-month intervals. All individuals who progressed were adopted to assess OS. Eligibility Individuals with histologically confirmed, recurrent or prolonged endometrial carcinoma after at least one chemotherapeutic routine, and with at least one measurable lesion (at least 20 mm by palpation, x-ray, CT scan, or MRI, or at least 10 mm by spiral CT scan) were eligible for this trial. Each individual provided written consent for the protocol including the translational study component with annual Institution Review Board authorization at each of the participating organizations and laboratories in accordance with local, state, and federal regulations and guidelines. Study Design and Treatment Plan Gefitinib was given at a dose of 500 mg Tacrolimus monohydrate per day orally. Each 28 day time period was regarded as a cycle. If side effects were not severe and requirements for monitoring toxicity were met, individuals were eligible to remain on the study agent until progression. Management of Toxicity In general, gefitinib was withheld in individuals with grade 2 or higher toxicities until resolution, and individuals were then restarted on a reduced dose of 250 mg/day. No dose reductions below 250 mg were allowed. If toxicities did not resolve to grade 1 or baseline.
